Peps
Degarelix
Degarelix is a GnRH antagonist used in prostate-cancer hormone therapy. PRONOUNCE examined cardiovascular events against leuprolide but ended before its planned enrollment.
Prescription medicines
Read the risks →Peptides that flag pregnancy or breastfeeding
These 18 profiles mention pregnancy or breastfeeding in their Risks & interactions section, from the FDA label for approved drugs or from published studies for research compounds. Open a profile and read that section to see exactly why.
A peptide that isn't listed may simply have no human safety data, which doesn't make it safe for you. Dashed tags on investigational GLP-1 drugs come from the labels of approved drugs in the same class. Not medical advice: talk to a doctor or pharmacist about your own situation. All peptides · Heart or blood pressure problems · Blood thinners or bleeding problems · Diabetes or blood-sugar medicines · Cancer, now or in the past · Kidney problems · Liver problems
Efpeglenatide
Efpeglenatide is an exendin-based GLP-1 receptor agonist. AMPLITUDE-O examined cardiovascular and kidney outcomes in a high-risk type 2 diabetes population.
Research topics
Read the risks →
Enfuvirtide
Enfuvirtide is an HIV fusion inhibitor with historical combination-treatment evidence. MedlinePlus reports that the injection has been discontinued in the United States.
Clinical medicines
Read the risks →
Enlicitide
Enlicitide is a ring-shaped peptide designed to block PCSK9, the same target as the antibody medicines Repatha and Praluent, but taken as a daily pill instead of an injection. The FDA approved it in July 2026 under the brand name Lipfendra to lower LDL cholesterol in adults with high cholesterol.
Prescription medicines
Read the risks →
HCG
Human chorionic gonadotropin is a glycoprotein hormone involved in reproductive signaling. The featured study compared hormonal approaches in men with hypogonadism seeking to preserve fertility.
Research topics
Read the risks →
Leuprolide
Leuprolide is a GnRH agonist used to control sex-hormone signaling in several conditions. It belongs to a different pathway from growth-hormone secretagogues.
Prescription medicines
Read the risks →
Liraglutide
Liraglutide is an incretin medicine with distinct diabetes and weight-management product contexts. Its benefits should be tied to the exact indication and population.
Prescription medicines
Read the risks →
Mazdutide
Mazdutide is a dual GLP-1 and glucagon receptor agonist studied for weight management. GLORY-1 tested it in Chinese adults with overweight or obesity.
Research topics
Read the risks →
Oxytocin
Oxytocin is a peptide hormone used in supervised obstetric care. Its established clinical context should be separated from popular social or wellness claims.
Prescription medicines
Read the risks →
Pemvidutide
Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis (MASH). Its liver-biopsy outcomes should be separated from weight-loss claims.
Research topics
Read the risks →
Retatrutide
Retatrutide is a triple-receptor agonist investigated for obesity and related metabolic conditions. Its trial identity differs from unverified coded seller listings.
Investigational
Read the risks →
Semaglutide
Semaglutide is an incretin medicine with product-specific uses in diabetes, weight management, and other defined conditions. Brand and formulation matter.
Prescription medicines
Read the risks →
Survodutide
Survodutide is a dual GLP-1 and glucagon receptor agonist. A 2026 phase 3 publication reports weight outcomes in adults with obesity or overweight without diabetes.
Research topics
Read the risks →
Terlipressin
Terlipressin is a vasopressin-related medicine used in a specific hepatorenal-syndrome setting. Its kidney-function results must be considered with the risk of serious respiratory complications.
Prescription medicines
Read the risks →
Tesamorelin
Tesamorelin is a prescription peptide for excess abdominal fat in HIV-associated lipodystrophy. It is not a general weight-loss medicine.
Prescription medicines
Read the risks →
Tirzepatide
Tirzepatide is a dual-incretin medicine with distinct product and indication contexts. Its clinical-trial material is not interchangeable with a research-use vial.
Prescription medicines
Read the risks →
TRH (thyrotropin-releasing hormone)
TRH is one of the body's own hormones: a tiny peptide made in the brain that tells the pituitary gland to release thyroid-stimulating hormone. A synthetic version, protirelin, was long used in a hospital test of thyroid and pituitary function. Researchers have also studied it in small trials for fatigue, depression and nerve diseases.
Research topics
Read the risks →
Triptorelin
Triptorelin is a GnRH agonist used for hormone suppression in clinical settings. The featured breast-cancer analysis included several ways of achieving ovarian suppression.
Prescription medicines
Read the risks →See something wrong on this page? Report a mistake · Corrections